Volume | 137,093 |
|
|||||
News | - | ||||||
Day High | 1.70 | Low High |
|||||
Day Low | 1.50 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Aptose Biosciences Inc | APTO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.50 | 1.50 | 1.70 | 1.66 | 1.50 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
683 | 137,093 | US$ 1.61 | US$ 221,312 | - | 1.36 - 10.125 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:16:16 | formt | 146 | US$ 1.61 | USD |
Aptose Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
502.35M | 7.54M | - | 0 | -41.82M | -5.54 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aptose Biosciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APTO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.51 | 1.70 | 1.46 | 1.54 | 63,637 | 0.10 | 6.62% |
1 Month | 1.90 | 1.90 | 1.36 | 1.61 | 75,054 | -0.29 | -15.26% |
3 Months | 2.39 | 2.60 | 1.36 | 1.90 | 92,112 | -0.78 | -32.64% |
6 Months | 2.91 | 3.32 | 1.36 | 2.16 | 71,246 | -1.30 | -44.67% |
1 Year | 9.702 | 10.125 | 1.36 | 5.06 | 98,717 | -8.09 | -83.41% |
3 Years | 89.10 | 96.90 | 1.36 | 35.07 | 474,983 | -87.49 | -98.19% |
5 Years | 30.75 | 138.7875 | 1.36 | 64.37 | 779,662 | -29.14 | -94.76% |
Aptose Biosciences Description
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. |